Diamondback Coronary
Payments companies reported to CMS as associated with Diamondback Coronary. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Diamondback Coronary, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Diamondback Coronary
These are the largest totals companies reported as associated with Diamondback Coronary. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Antonis Pratsos | Broomall, PA | Interventional Cardiology | $43,483.99 |
| Sarang Mangalmurti | Bryn Mawr, PA | Cardiovascular Disease | $36,761.22 |
| Sean Janzer | York, PA | Interventional Cardiology | $36,281.81 |
| Thomas Mcgarry | Oklahoma City, OK | Interventional Cardiology | $30,660.02 |
| Thom Dahle | Saint Cloud, MN | Interventional Cardiology | $26,198.11 |
| Stephen Kidd | Saint Cloud, MN | Interventional Cardiology | $24,846.01 |
| Matthew Whitbeck | Coon Rapids, MN | Cardiovascular Disease | $21,287.02 |
| Byung Park | Dallas, TX | Interventional Cardiology | $21,104.58 |
| Amir Kaki | Detroit, MI | Interventional Cardiology | $21,050.16 |
| Jeffrey Tyler | Orange, CA | Interventional Cardiology | $20,643.22 |
Prescribed Diamondback Coronary?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.